These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
90 related articles for article (PubMed ID: 19855161)
1. The role of mTORC1 pathway in intestinal tumorigenesis. Fujishita T; Aoki M; Taketo MM Cell Cycle; 2009 Nov; 8(22):3684-7. PubMed ID: 19855161 [TBL] [Abstract][Full Text] [Related]
2. Inhibition of the mTORC1 pathway suppresses intestinal polyp formation and reduces mortality in ApcDelta716 mice. Fujishita T; Aoki K; Lane HA; Aoki M; Taketo MM Proc Natl Acad Sci U S A; 2008 Sep; 105(36):13544-9. PubMed ID: 18768809 [TBL] [Abstract][Full Text] [Related]
3. mTORC1 inhibition restricts inflammation-associated gastrointestinal tumorigenesis in mice. Thiem S; Pierce TP; Palmieri M; Putoczki TL; Buchert M; Preaudet A; Farid RO; Love C; Catimel B; Lei Z; Rozen S; Gopalakrishnan V; Schaper F; Hallek M; Boussioutas A; Tan P; Jarnicki A; Ernst M J Clin Invest; 2013 Feb; 123(2):767-81. PubMed ID: 23321674 [TBL] [Abstract][Full Text] [Related]
4. Inhibition of mTORC1 by RAD001 (everolimus) potentiates the effects of 1,25-dihydroxyvitamin D(3) to induce growth arrest and differentiation of AML cells in vitro and in vivo. Yang J; Ikezoe T; Nishioka C; Ni L; Koeffler HP; Yokoyama A Exp Hematol; 2010 Aug; 38(8):666-76. PubMed ID: 20382200 [TBL] [Abstract][Full Text] [Related]
9. Distinct signaling mechanisms of mTORC1 and mTORC2 in glioblastoma multiforme: a tale of two complexes. Jhanwar-Uniyal M; Gillick JL; Neil J; Tobias M; Thwing ZE; Murali R Adv Biol Regul; 2015 Jan; 57():64-74. PubMed ID: 25442674 [TBL] [Abstract][Full Text] [Related]
10. Inhibition of mTORC1 signaling reduces tumor growth but does not prevent cancer progression in a mouse model of thyroid cancer. Guigon CJ; Fozzatti L; Lu C; Willingham MC; Cheng SY Carcinogenesis; 2010 Jul; 31(7):1284-91. PubMed ID: 20299527 [TBL] [Abstract][Full Text] [Related]
12. Inhibition of mammalian target of rapamycin signaling potentiates the effects of all-trans retinoic acid to induce growth arrest and differentiation of human acute myelogenous leukemia cells. Nishioka C; Ikezoe T; Yang J; Gery S; Koeffler HP; Yokoyama A Int J Cancer; 2009 Oct; 125(7):1710-20. PubMed ID: 19507250 [TBL] [Abstract][Full Text] [Related]
13. Benchmarking effects of mTOR, PI3K, and dual PI3K/mTOR inhibitors in hepatocellular and renal cell carcinoma models developing resistance to sunitinib and sorafenib. Serova M; de Gramont A; Tijeras-Raballand A; Dos Santos C; Riveiro ME; Slimane K; Faivre S; Raymond E Cancer Chemother Pharmacol; 2013 May; 71(5):1297-307. PubMed ID: 23479136 [TBL] [Abstract][Full Text] [Related]
14. Not all substrates are treated equally: implications for mTOR, rapamycin-resistance and cancer therapy. Choo AY; Blenis J Cell Cycle; 2009 Feb; 8(4):567-72. PubMed ID: 19197153 [TBL] [Abstract][Full Text] [Related]
15. The pharmacology of mTOR inhibition. Guertin DA; Sabatini DM Sci Signal; 2009 Apr; 2(67):pe24. PubMed ID: 19383975 [TBL] [Abstract][Full Text] [Related]
16. PIK3CA mutation, but not PTEN loss of function, determines the sensitivity of breast cancer cells to mTOR inhibitory drugs. Weigelt B; Warne PH; Downward J Oncogene; 2011 Jul; 30(29):3222-33. PubMed ID: 21358673 [TBL] [Abstract][Full Text] [Related]
17. Preclinical efficacy of dual mTORC1/2 inhibitor AZD8055 in renal cell carcinoma harboring a TFE3 gene fusion. Kauffman EC; Lang M; Rais-Bahrami S; Gupta GN; Wei D; Yang Y; Sourbier C; Srinivasan R BMC Cancer; 2019 Sep; 19(1):917. PubMed ID: 31519159 [TBL] [Abstract][Full Text] [Related]